ASCO GU 2026 Kidney Cancer

Viewing 1-20 of 28 articles

ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC

ASCO GU 2026: Emerging Tools in Imaging in Renal Cell Carcinoma

ASCO GU 2026: Imaging for Renal Cell Carcinoma: Current State of the Art

ASCO GU 2026: Efficacy and Safety of Avelumab + Axitinib Versus Sunitinib in Patients with Very Favorable Risk Advanced RCC: Subgroup Analysis from the JAVELIN Renal 101 Trial

ASCO GU 2026: Circulating KIM-1 in Metastatic RCC with Divergent Histologies: Biomarker Analysis of the CAN-I Trial

ASCO GU 2026: Characterization of Depth and Durability of Response in Patients with Previously Untreated Advanced RCC Who Received Cabozantinib + Nivolumab: Long-Term Follow-up and Exploratory Analysis of CheckMate 9ER

ASCO GU 2026: First Results of a Dose-Escalation Study Evaluating CBM588 with Nivolumab + Ipilimumab in Metastatic RCC

ASCO GU 2026: Adjuvant Pembrolizumab in Non-Clear Cell RCC After Nephrectomy: An International Multicenter Study

ASCO GU 2026: Response of Venous Tumor Thrombi in RCC to Immune Checkpoint Inhibitor Therapy: A Multicenter Retrospective Cohort Study

ASCO GU 2026: Geographic Disparities in the Availability of RCC Clinical Trials in the US

ASCO GU 2026: Head to Head Comparison of Pembrolizumab + Axitinib Versus Pembrolizumab + Lenvatinib in Metastatic RCC: Real World Data from the Canadian Kidney Cancer Information System Database

ASCO GU 2026: Phase 1b/2 KEYMAKER-U03 Substudy 03C of Belzutifan + Zanzalintinib or Belzutifan Monotherapy for Recurrent Clear Cell RCC During or After Anti-PD-(L)1 Therapy

ASCO GU 2026: A Randomized Phase 2 Trial of Nivolumab + Relatlimab + Ipilimumab Versus Nivolumab + Ipilimumab in First Line Advanced RCC

ASCO GU 2026: The Phase II IVORY Trial: Ivonescimab in Metastatic Clear Cell RCC After Immune Checkpoint Inhibitor Therapy

ASCO GU 2026: STRIKE! (Alliance A032201): Short Term Intensified Pembrolizumab and Tivozanib for High-Risk RCC

ASCO GU 2026: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment-Naïve Patients with Advanced Clear Cell RCC

ASCO GU 2026: Biomarker Analysis from the Phase 2 LITESPARK-013 Study of Two Different Belzutifan Doses in Participants with Advanced Clear Cell RCC

ASCO GU 2026: Ultra-Sensitive Whole-Genome Sequencing-Based Molecular Residual Disease Detection in Resectable RCC: Preliminary Results from the MONSTAR-SCREEN-3 Study

ASCO GU 2026: KEYMAKER-U03 Substudy 03B: Novel Investigative Regimens for Previously Treated Advanced Clear Cell RCC

ASCO GU 2026: Fruquintinib + Serplulimab as First Line Therapy in Metastatic or Unresectable Non-Clear Cell RCC: Updated Efficacy and Safety Data from a Multicenter, Single-Arm, Phase II Trial

1
2